The Big Mo

Years ago, before Exubera hit the market analysts were jumping on the Pfizer bandwagon writing glowing reports explaining why this drug would become a mega-blockbuster. Some projecting sales reaching $4 billion per year. Next came Afrezza and once again the initial analysts’ reports were very positive sending MannKind (NASDAQ: MNKD) shares into the stratosphere. Yep everyone seemed to believe that inhaled insulin was a guaranteed hit.

Today Exubera is a distant memory while Afrezza continues to struggle. We mention this as Tandem (NASDAQ: TNDM) a company that was on the verge of closing only a few short months ago . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

This entry was posted in Email Alerts. Bookmark the permalink.